Roche Susvimo EU Approval Expands Treatment Options for Neovascular Age-Related Macular Degeneration

Roche has received European Commission approval for Susvimo, marking an important development in the treatment of neovascular age-related macular degeneration, commonly known as wet AMD. The approval covers adults with nAMD who have achieved stable disease after previously responding to treatment with a VEGF inhibitor.

Susvimo uses a refillable ocular implant known as Contivue to continuously deliver a customised formulation of ranibizumab inside the eye. For pharmaceutical buyers and healthcare supply chains, the approval demonstrates how advanced drug delivery technologies are creating new requirements beyond conventional active pharmaceutical ingredients and standard injectable formulations.

European Approval Opens a New Chapter for Susvimo

The European Commission issued the marketing authorisation in September 2026 following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use in July. The EMA lists Susvimo as indicated for adult patients with nAMD who have stable disease following a previous response to intravitreal VEGF inhibitor treatment.

Roche developed Susvimo around a refillable implant system rather than repeated conventional eye injections. The Contivue platform includes the implant and supporting devices required to initially fill, insert, refill and remove the implant when required.

The approval follows European regulatory progress that began with the CE mark for Roche's Port Delivery Platform in 2025. The platform became known as Contivue in the European Union.

Why Neovascular AMD Creates a Significant Treatment Need

Neovascular AMD affects the macula, the area of the eye responsible for sharp central vision. The wet form can involve abnormal blood vessel growth beneath the macula, which can damage retinal tissue and cause serious vision loss if treatment does not control the disease.

Roche estimates that approximately 1.7 million people in the European Union are affected by nAMD. Globally, around 20 million people live with the condition, making the disease an important area for ophthalmic pharmaceutical development.

The continuing need for treatment also creates pressure to improve treatment durability. Roche reports that many nAMD patients cannot extend their dosing interval beyond eight weeks and that 40% discontinue treatment within two years.

For healthcare procurement teams, these factors can increase interest in therapies that reduce administration frequency while maintaining disease control.

How the Contivue and Susvimo System Works

Susvimo contains a customised formulation of ranibizumab, a VEGF inhibitor. The medicine is delivered continuously through the Contivue refillable implant rather than relying solely on repeated intravitreal injections.

Ranibizumab works by inhibiting VEGF-A, a signalling protein associated with abnormal blood vessel formation and vascular leakage. The delivery system therefore combines a recognised anti-VEGF therapeutic mechanism with a different method of administering the medicine over time.

The Contivue implant requires a one-time outpatient surgical procedure for insertion. Patients can then receive refills through the implant according to the treatment schedule established for the product.

This model changes the procurement profile of treatment. Supply planning must account not only for the pharmaceutical formulation but also for the specialised implant and associated devices used in the delivery process.

Clinical Data Supporting the European Decision

The European approval draws on data from the Phase III Archway study and supporting Phase II Ladder and Portal studies. Roche reports that Archway showed vision outcomes with Susvimo remained equivalent to monthly intravitreal ranibizumab injections.

Longer-term Portal data also supported maintenance of vision for up to seven years. Roche reports that approximately 95% of patients receiving two refills per year required no additional anti-VEGF treatment.

The data are particularly relevant to the commercial development of long-duration drug delivery platforms. Pharmaceutical companies and their suppliers increasingly need to consider stability, formulation performance and compatibility with specialised delivery technologies alongside conventional manufacturing requirements.

Susvimo also represents an example of how pharmaceutical innovation can combine an established active ingredient with a new administration platform. This approach may allow companies to pursue differentiated treatment options without relying entirely on the discovery of new molecular targets.

What the EU Approval Means for Pharmaceutical Supply Chains

The approval may create additional procurement activity around specialised pharmaceutical and medical technology supply chains. Unlike a conventional injectable medicine, Susvimo operates as an integrated therapeutic delivery system involving both drug formulation and implant technology.

For procurement managers and pharmaceutical distributors, several factors deserve attention:

• Specialised product handling: Products involving sophisticated drug delivery systems may require more detailed logistics and inventory procedures than conventional pharmaceutical chemicals.

• Regulatory documentation: European pharmaceutical procurement requires appropriate documentation covering product identity, regulatory status, quality and supply arrangements.

• Supply continuity: Long-term treatment programmes require dependable availability because interruptions can affect clinical treatment schedules.

• Specialised manufacturing: Refillable implants require manufacturing capabilities that differ substantially from standard pharmaceutical formulation and packaging operations.

• Regional market access: European Commission approval provides a regulatory pathway for marketing within the European Union, subject to applicable requirements and commercial arrangements.

These considerations demonstrate why procurement teams should evaluate pharmaceutical supply chains beyond unit price alone. Documentation, reliability, technical specifications and regulatory compliance can influence the practical value of a supply agreement.

The Role of Advanced Drug Delivery in Ophthalmology

Susvimo reflects a broader shift toward delivery systems designed to extend the duration of ophthalmic treatments. Conventional eye injections can require repeated clinic visits, creating an ongoing administration burden for patients and healthcare providers.

Continuous delivery approaches attempt to address this challenge by maintaining drug exposure through an implanted system. Roche describes Contivue with Susvimo as the first continuous delivery treatment for nAMD approved in Europe.

The platform could also have broader strategic significance for Roche. The company says it is evaluating other molecules that could potentially use the Port Delivery Platform, with the aim of developing additional treatment options for patients using Contivue.

For the pharmaceutical supply sector, this points toward continued demand for specialised materials, formulation expertise, sterile manufacturing capabilities and device integration.

What Procurement Teams Should Watch After Approval

European approval is an important regulatory milestone, but commercial availability and procurement activity will depend on individual markets, healthcare systems and distribution arrangements.

Buyers evaluating ophthalmic pharmaceutical opportunities should monitor several developments:

• European market rollout and national procurement activity following the central marketing authorisation.

• Demand for ranibizumab-based products and associated delivery technologies.

• Expansion of continuous drug delivery platforms into additional ophthalmic indications.

• Manufacturing and supply capacity for specialised implant-based treatment systems.

• Future Roche developments involving other molecules and the Contivue platform.

The European approval also reinforces the importance of tracking regulatory developments when planning pharmaceutical supply strategies. A regulatory decision can create new demand patterns across manufacturers, distributors and healthcare procurement organisations.

The Bottom Line for Procurement Teams

Roche's European Commission approval of Susvimo adds a continuous drug delivery option for eligible patients with neovascular age-related macular degeneration. The product combines a customised ranibizumab formulation with the refillable Contivue ocular implant and is designed to reduce the frequency of conventional eye injections.

For pharmaceutical buyers, the development illustrates how the ophthalmic market is moving toward integrated medicines and delivery platforms. Companies involved in pharmaceutical sourcing, specialty distribution and healthcare procurement should monitor demand for advanced formulations and delivery technologies as the European market develops.

Ready to source Ascorbic Acid from verified global suppliers? Explore competitive offers on our platform today.